Cardiogen (20mg)

Cardiogen (20mg) is a lyophilized research peptide synthesized, purified, and lyophilized in the USA. Each production batch is purified by repeated rounds of reverse-phase HPLC and identity-confirmed by mass spectrometry.

Studies of Cardiogen (20mg) typically combine purity verification with functional assays to support reproducible results.

Researchers evaluating Cardiogen (20mg) document batch COA data and storage conditions as part of experimental design.

Cardiogen (20mg) is often included in comparative panels alongside related peptides to characterize research utility.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Cardiogen (20mg). Summaries are provided for orientation only and reflect the cited sources.

Peptide medicines: past, present, future^[1] — This review by Khavinson discussed peptide medicines and explicitly listed cardiogen among short tissue-specific peptides synthesized from amino acids. The author described how such short peptides regulate gene expression and protein synthesis in their target tissues. The work positions cardiogen within the broader framework of bioregulatory peptide therapy. (Clinical Medicine (Russian journal) 2020)

Peptides and Ageing^[2] — This review addressed the role of short tissue-specific peptides in ageing, including cardiovascular tetrapeptides such as cardiogen. The author examined how these peptides may help regulate cardiac function and counteract age-related decline. The article supports the concept of tissue-specific peptide bioregulators for cardiovascular health. (Neuro Endocrinology Letters 2002)

Mechanisms underlying geroprotective effects of peptides^[3] — This study examined the mechanisms underlying the geroprotective effects of short tissue-specific peptides. The authors described how these peptides normalize protein synthesis and gene expression, with particular relevance to cardiovascular aging. The findings help explain the proposed basis for peptides such as cardiogen in age-related conditions. (Bulletin of Experimental Biology and Medicine 2002)

References

1. Khavinson VKh. "Peptide medicines: past, present, future." Clinical Medicine (Russian journal). 2020. www.r-5.org/files/books/medicine/vein-blood/peptide-mixtu…
2. Khavinson VKh. "Peptides and Ageing." Neuro Endocrinology Letters. 2002. pubmed.ncbi.nlm.nih.gov/12374906/
3. Khavinson VKh, Malinin VV. "Mechanisms underlying geroprotective effects of peptides." Bulletin of Experimental Biology and Medicine. 2002. pubmed.ncbi.nlm.nih.gov/12170291/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.